Ronald Moss, MD, FAAAAI, CEO of DIOSynVax, presented the data during the late-breaking session, highlighting the vaccine's ability to generate strong, broad neutralizing immune responses capable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback